|
|
|
| Relationship of plasma levels of Aβ1-42 and Tau protein with cognitive impairment in patients with severe Parkinson′s disease |
| DU Jie WEI Liang ZHAO Xi ZHAO Lige LIU Fengbing |
| Department of Neurology, the People′s Hospital of Kaizhou District, Chongqing 405400, China |
|
|
|
Abstract Objective To investigate the relationship of plasma levels of β-amyloid 1-42 (Aβ1-42) and Tau protein with cognitive impairment in patients with severe Parkinson′s disease (PD). Methods Sixty-four cases of severe PD that were treated in Department of Neurology , the People′s Hospital of Kaizhou District from April 2016 to April 2018 were enrolled. They were divided into three groups according to the scores of Montreal cognitive assessment scale (MoCA): severe cognitive impairment group (13 cases), mild-to-moderate cognitive impairment group (29 cases) and normal cognitive function group (22 cases). The levels of plasma Aβ1-42 and Tau protein were compared among the groups. Pearson correlation analysis was used to analyze the correlation between levels of plasma Aβ1-42 and Tau protein with the MoCA scores in PD patients. Results There were statistically significant differences in the levels of plasma Aβ1-42 and Tau protein among the three groups (P ＜ 0.05). The level of plasma Aβ1-42 in severe cognitive impairment group was significantly lower than that in mild-to-moderate cognitive impairment group and normal cognitive function group, while the Tau protein level of severe cognitive impairment group was significantly higher than that in mild-to-moderate cognitive impairment group and normal cognitive function group; the plasma Aβ1-42 level in mild-to-moderate cognitive impairment group was significantly lower than that in normal cognitive function group while the Tau protein level was significantly higher than that in normal cognitive function group, the differences were significant (P ＜ 0.05). Pearson correlation analysis showed that plasma Aβ1-42 level was positively correlated with MoCA score (r = 0.345, P ＜ 0.05), and plasma Tau level was negatively correlated with MoCA score (r = -0.416, P ＜ 0.05). Conclusion Level changes of plasma Aβ1-42 and Tau may be associated with cognitive impairment in PD patients, or they may be used as potential early predictors of cognitive impairment in PD patients.
|
|
|
|
|
|
[1] 陈旭，耿翔.帕金森病发病机制新进展[J].中华老年心脑血管病杂志，2014，16（9）：897-898.
[2] Kalia LV，Lang AE. Parkinson′s disease [J]. Lancet，2015， 386（9996）：896-912.
[3] 唐红梅，张玉虎，王丽娟.脑白质损害与帕金森病认知功能障碍的研究进展[J].中华老年心脑血管病杂志，2014， 16（3）：327-329.
[4] 徐菁，陈生弟.阿尔茨海默病中Tau蛋白和Aβ相互作用的研究进展[J].中国神经精神疾病杂志，2014，40（4）：251-254.
[5] Terziogluusak S，Negis Y，Karabulut DS，et al. Cellular model of Alzheimer′s disease：Aβ1-42 peptide induces amyloid deposition and a decrease in topo isomerase IIβ and Nurr1 expression [J]. Current Alzheimer Research，2017， 14（6）：636-644.
[6] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49（4）：268-271.
[7] 美国精神医学学会.精神障碍诊断与统计手册（案头参考书）[M].北京：北京大学出版社，2014：117-178.
[8] 高靓，张玉虎，王丽娟.帕金森病与神经免疫炎症研究的新进展[J].临床神经病学杂志，2014，27（3）：234-236.
[9] Ascherio A，Schwarzschild MA. The epidemiology of Parkinson′s disease：risk factors and prevention [J]. Lancet Neurology，2016，15（12）：1257-1272.
[10] 李政.帕金森病病因及发病机制的进展研究[J].国际神经病学神经外科学杂志，2014，41（4）：345-348.
[11] 陈文鑫，邓远飞，吴学良，等.MoCA量表在帕金森病轻度认知障碍筛查中的应用价值[J].卒中与神经疾病，2017， 24（2）：142-143.
[12] 徐珊瑚，林阁，朱银花，等.蒙特利尔认知评估量表在帕金森病伴轻度认知功能障碍患者中的应用研究[J].中国康复医学杂志，2015，30（3）：251-254.
[13] 韩丽珠，王文静，褚忠海，等.轻度认知障碍患者脑脊液中β-淀粉样蛋白42及磷酸化Tau蛋白的水平检测及意义[J].实用医学杂志，2014，30（19）：3079-3081.
[14] 王治国，战莹，武晓丹，等.血浆β淀粉样蛋白在阿尔茨海默病早期诊断中的临床价值[J].标记免疫分析与临床，2017，24（9）：976-978.
[15] 闫蓉，刘艾林，杜冠华.新型抗AD活性化合物DL0410降低Aβ毒性作用机制研究[J].中国药理学通报，2015， 31（b11）：204-205.
[16] 黄海，陈丽君，陈立艺，等.Aβ1-42寡聚体对大鼠认知功能的影响和神经毒性分析[J].解剖学杂志，2015，38（6）：698-701.
[17] Terrelonge JM，Marder KS，Weintraub D，et al. CSF β-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease [J]. J Mol Neurosci，2016，58（1）：88-92.
[18] Smolek T，Madari A，Farbakova J，et al. Tau hyperphosphorylation in synaptosomes and neuroinflammation are associated with canine cognitive impairment [J]. J Comp Neurol，2016，524（4）：874-895.
[19] 王琦.Aβ蛋白和tau蛋白与阿尔茨海默病的相关性研究进展[J].医学综述，2013，19（11）：1921-1923.
[20] Shekhar S，Kumar R，Rai N，et al. Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer′s Disease and Mild Cognitive Impairment Patients [J]. Plos One，2016，11（7）：e0159099.
[21] 曹帆帆，张登海，王莹，等.NAC对Aβ25-35诱导SH-SY5Y细胞Tau蛋白过度磷酸化影响的研究[J].临床和实验医学杂志，2016，15（20）：1984-1987.
[22] 吴煜，邹显巍，罗嫚.帕金森病治疗的新进展[J].河北医学，2017，23（9）：1573-1577. |
|
|
|
